Adamas Pharmaceuticals, Inc. (ADMS): Price and Financial Metrics


Adamas Pharmaceuticals, Inc. (ADMS)

Today's Latest Price: $5.54 USD

0.08 (-1.42%)

Updated Jan 27 4:00pm

Add ADMS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ADMS Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for ADMS is -2.02 -- better than only 4.17% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -7.55 for Adamas Pharmaceuticals Inc; that's greater than it is for just 2.3% of US stocks.
  • As for revenue growth, note that ADMS's revenue has grown 35.26% over the past 12 months; that beats the revenue growth of 86.12% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Adamas Pharmaceuticals Inc, a group of peers worth examining would be TXMD, NEOS, MNKD, ASPS, and TELA.
  • ADMS's SEC filings can be seen here. And to visit Adamas Pharmaceuticals Inc's official web site, go to www.adamaspharma.com.

ADMS Stock Price Chart Interactive Chart >

Price chart for ADMS

ADMS Price/Volume Stats

Current price $5.54 52-week high $6.02
Prev. close $5.62 52-week low $1.90
Day low $5.39 Volume 894,501
Day high $5.94 Avg. volume 330,906
50-day MA $4.65 Dividend yield N/A
200-day MA $3.82 Market Cap 158.01M

Adamas Pharmaceuticals, Inc. (ADMS) Company Bio


Adamas Pharmaceuticals is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company was founded in 2000 and is based in Emeryville, California.


ADMS Latest News Stream


Event/Time News Detail
Loading, please wait...

ADMS Latest Social Stream


Loading social stream, please wait...

View Full ADMS Social Stream

Latest ADMS News From Around the Web

Below are the latest news stories about Adamas Pharmaceuticals Inc that investors may wish to consider to help them evaluate ADMS as an investment opportunity.

Adamas Provides Preliminary Fourth Quarter and Full Year 2020 Total Revenues and Key Business Drivers for 2021

\-- Total revenues expected to be $20.8 million for fourth quarter 2020 and $74.2 million for full year 2020 -- \-- Product sales of GOCOVRI® expected to be $19.8 million for fourth quarter 2020 and $71.2 million for full year 2020 --\-- Total prescriptions of GOCOVRI of approximately 8,165 for fourth quarter 2020 and approximately 31,070* for full year 2020 -- EMERYVILLE, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today provides preliminary unaudited total revenues for the fourth quarter and full year 2020 and key business drivers for 2021.“I am proud of our team’s resilience, ability to adapt, and unwaver...

Yahoo | January 13, 2021

Adamas to Present at Upcoming ICR Conference

EMERYVILLE, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering…

GlobeNewswire | January 7, 2021

Would Shareholders Who Purchased Adamas Pharmaceuticals' (NASDAQ:ADMS) Stock Three Years Be Happy With The Share price Today?

It's nice to see the Adamas Pharmaceuticals, Inc. ( NASDAQ:ADMS ) share price up 12% in a week. But that is meagre...

Yahoo | January 6, 2021

Adamas Completes Acquisition of OSMOLEX ER®

Royalty-Backed Loan Agreement Amendment Effective with OSMOLEX ER AcquisitionEMERYVILLE, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the closing of the settlement of patent litigation with Osmotica Pharmaceutical US LLC, a subsidiary of Osmotica Pharmaceuticals plc and completes the acquisition of the global rights to OSMOLEX ER®. As previously disclosed, the amended Royalty-Backed Loan Agreement with HealthCare Royalty Partners is now effective with the closing of the acquisition of OSOMOLEX ER. Through this acquisition, OSMOLEX ER joins the Adamas portfolio which includes GOCOVRI® (amantadi...

Yahoo | January 5, 2021

Adamas to Present at Upcoming H.C. Wainwright Conference

EMERYVILLE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering…

GlobeNewswire | January 4, 2021

Read More 'ADMS' Stories Here

ADMS Price Returns

1-mo 28.54%
3-mo 68.90%
6-mo 123.39%
1-year 4.53%
3-year -86.72%
5-year -67.68%
YTD 27.94%
2020 14.25%
2019 -55.62%
2018 -74.80%
2017 100.53%
2016 -40.32%

Continue Researching ADMS

Here are a few links from around the web to help you further your research on Adamas Pharmaceuticals Inc's stock as an investment opportunity:

Adamas Pharmaceuticals Inc (ADMS) Stock Price | Nasdaq
Adamas Pharmaceuticals Inc (ADMS) Stock Quote, History and News - Yahoo Finance
Adamas Pharmaceuticals Inc (ADMS) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7873 seconds.